Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($) |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Accumulated Other Comprehensive Income (Loss) [Line Items] | ||||
| Number of Warrants Outstanding, Beginning Balance | 2,814,057 | 2,814,057 | 2,814,057 | |
| Weighted Average Exercise Price, Outstanding Beginning Balance | $ 4.97 | $ 4.97 | $ 4.97 | |
| Weighted Average Remaining Contractual Term (Years), Outstanding Balance | 1 year 11 months 12 days | 2 years 2 months 12 days | 2 years 5 months 12 days | 3 years 5 months 26 days |
| Aggregate Intrinsic Value, Outstanding Beginning Balance | ||||
| Number of Warrants, Granted | ||||
| Weighted Average Exercise Price, Granted | ||||
| Number of Warrants, Exercised | ||||
| Weighted Average Exercise Price, Exercised | ||||
| Number of Warrants Outstanding, Ending Balance | 2,814,057 | 2,814,057 | 2,814,057 | 2,814,057 |
| Weighted Average Exercise Price, Outstanding Ending Balance | $ 4.97 | $ 4.97 | $ 4.97 | $ 4.97 |
| Aggregate Intrinsic Value, Outstanding Ending Balance | ||||
| X | ||||||||||
- Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the warrants No definition available.
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants. No definition available.
|
| X | ||||||||||
- Definition Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term 2 No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|